Best Major Pharmaceuticals Stocks 2021

Filters
Select UI View

Vs.
Select Industry

Market Cap

$ 1.76 M to $ 754.01 B

Stock Prices

$0.07 to $793.56

Returns

-63.23% to 926.65%

Price / Earning Ratio

-74.61 to 865.04

Lilly(Eli) & Co

LLY

Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. It was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today it remains true to that mission in all its work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Symbol
LLY

Exchange
NEW YORK STOCK EXCHANGE INC.

Sector
Manufacturing

Website
www.lilly.com

Market Cap
$ 754.01 B

P/E Ratio
136.82

YTD Change
35.87%

52 Week Range
$306.75 - $799.92

Stock Name
Lilly(Eli) & Co

CEO
David Ricks

Employees
2,020

Address
Indianapolis , Indiana

Lilly(Eli) & Co or LLY is traded on NEW YORK STOCK EXCHANGE INC.. The total market value of the company is $ 754.01 B. David Ricks is the CEO of the company. Total employees of Lilly(Eli) & Co are 2,020. The P/E Ratio of Lilly(Eli) & Co is 136.82 and year till date stock price change percent is 35.87%.

Johnson & Johnson

JNJ

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Symbol
JNJ

Exchange
NEW YORK STOCK EXCHANGE INC.

Sector
Manufacturing

Website
www.jnj.com

Market Cap
$ 384.82 B

P/E Ratio
11.64

YTD Change
2.76%

52 Week Range
$142.71 - $172.01

Stock Name
Johnson & Johnson

CEO
Alex Gorsky

Employees
134,500

Address
New Brunswick , New Jersey

Johnson & Johnson or JNJ is traded on NEW YORK STOCK EXCHANGE INC.. The total market value of the company is $ 384.82 B. Alex Gorsky is the CEO of the company. Total employees of Johnson & Johnson are 134,500. The P/E Ratio of Johnson & Johnson is 11.64 and year till date stock price change percent is 2.76%.

Merck & Co Inc

MRK

For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of its mission to save and improve lives. It demonstrates its commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals - including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases - as we aspire to be the premier research-intensive biopharmaceutical company in the world.

Symbol
MRK

Exchange
NEW YORK STOCK EXCHANGE INC.

Sector
Manufacturing

Website
www.merck.com

Market Cap
$ 313.95 B

P/E Ratio
865.04

YTD Change
14.09%

52 Week Range
$98.43 - $130.24

Stock Name
Merck & Co Inc

CEO
Kenneth Frazier

Employees
73,500

Address
Kenilworth , New Jersey

Merck & Co Inc or MRK is traded on NEW YORK STOCK EXCHANGE INC.. The total market value of the company is $ 313.95 B. Kenneth Frazier is the CEO of the company. Total employees of Merck & Co Inc are 73,500. The P/E Ratio of Merck & Co Inc is 865.04 and year till date stock price change percent is 14.09%.

Abbvie Inc

ABBV

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The Company strives to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

Symbol
ABBV

Exchange
NEW YORK STOCK EXCHANGE INC.

Sector
Manufacturing

Website
www.abbvie.com

Market Cap
$ 312.01 B

P/E Ratio
64.94

YTD Change
15.28%

52 Week Range
$127.03 - $179.94

Stock Name
Abbvie Inc

CEO
Richard Gonzalez

Employees
2,020

Address
North Chicago , Illinois

Abbvie Inc or ABBV is traded on NEW YORK STOCK EXCHANGE INC.. The total market value of the company is $ 312.01 B. Richard Gonzalez is the CEO of the company. Total employees of Abbvie Inc are 2,020. The P/E Ratio of Abbvie Inc is 64.94 and year till date stock price change percent is 15.28%.

Pfizer Inc.

PFE

Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives. It strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with its responsibility as one of the world's premier innovative biopharmaceutical companies, it collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, it has worked to make a difference for all who rely on it. It routinely posts information that may be important to investors on its website at www.Pfizer.com.

Symbol
PFE

Exchange
NEW YORK STOCK EXCHANGE INC.

Sector
Manufacturing

Website
www.pfizer.com

Market Cap
$ 145.91 B

P/E Ratio
69.65

YTD Change
-9.07%

52 Week Range
$25.38 - $40.15

Stock Name
Pfizer Inc.

CEO
Albert Bourla

Employees
78,500

Address
New York , New York

Pfizer Inc. or PFE is traded on NEW YORK STOCK EXCHANGE INC.. The total market value of the company is $ 145.91 B. Albert Bourla is the CEO of the company. Total employees of Pfizer Inc. are 78,500. The P/E Ratio of Pfizer Inc. is 69.65 and year till date stock price change percent is -9.07%.

Bristol-Myers Squibb Co.

BMY

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Symbol
BMY

Exchange
NEW YORK STOCK EXCHANGE INC.

Sector
Manufacturing

Website
www.bms.com

Market Cap
$ 102.97 B

P/E Ratio
13.19

YTD Change
0.39%

52 Week Range
$47.58 - $68.93

Stock Name
Bristol-Myers Squibb Co.

CEO
Giovanni Caforio

Employees
30,250

Address
New York , New York

Bristol-Myers Squibb Co. or BMY is traded on NEW YORK STOCK EXCHANGE INC.. The total market value of the company is $ 102.97 B. Giovanni Caforio is the CEO of the company. Total employees of Bristol-Myers Squibb Co. are 30,250. The P/E Ratio of Bristol-Myers Squibb Co. is 13.19 and year till date stock price change percent is 0.39%.

Karuna Therapeutics Inc

KRTX

Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.Karuna understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by these severe and disabling disorders. Utilizing itsextensive knowledge of neuroscience, the Company is harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples' lives.

Symbol
KRTX

Exchange
NASDAQ

Sector
Manufacturing

Website
karunatx.com

Market Cap
$ 12.13 B

P/E Ratio
-27.11

YTD Change
0.47%

52 Week Range
$158.38 - $321.45

Stock Name
Karuna Therapeutics Inc

CEO

Employees
63

Karuna Therapeutics Inc or KRTX is traded on NASDAQ. The total market value of the company is $ 12.13 B. is the CEO of the company. Total employees of Karuna Therapeutics Inc are 63. The P/E Ratio of Karuna Therapeutics Inc is -27.11 and year till date stock price change percent is 0.47%.

Apellis Pharmaceuticals Inc

APLS

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology.

Symbol
APLS

Exchange
NASDAQ

Sector
Manufacturing

Website
apellis.com

Market Cap
$ 7.82 B

P/E Ratio

YTD Change
8.27%

52 Week Range
$19.83 - $94.75

Stock Name
Apellis Pharmaceuticals Inc

CEO
Cedric Francois

Employees
374

Address
Waltham , Massachusetts

Apellis Pharmaceuticals Inc or APLS is traded on NASDAQ. The total market value of the company is $ 7.82 B. Cedric Francois is the CEO of the company. Total employees of Apellis Pharmaceuticals Inc are 374. The P/E Ratio of Apellis Pharmaceuticals Inc is and year till date stock price change percent is 8.27%.

Reata Pharmaceuticals Inc

RETA

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata's two most advanced clinical candidates, bardoxolone and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.

Symbol
RETA

Exchange
NASDAQ

Sector
Manufacturing

Website
www.reatapharma.com

Market Cap
$ 5.79 B

P/E Ratio
-74.61

YTD Change
0.02%

52 Week Range
$0.00 - $172.46

Stock Name
Reata Pharmaceuticals Inc - Class A

CEO
J. Warren Huff

Employees
267

Address
Plano , Texas

Reata Pharmaceuticals Inc or RETA is traded on NASDAQ. The total market value of the company is $ 5.79 B. J. Warren Huff is the CEO of the company. Total employees of Reata Pharmaceuticals Inc are 267. The P/E Ratio of Reata Pharmaceuticals Inc - Class A is -74.61 and year till date stock price change percent is 0.02%.

Forty Seven, Inc.

FTSV

Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.

Symbol
FTSV

Exchange
NASDAQ

Sector
Health Technology

Website
http://www.fortyseveninc.com

Market Cap
$ 4.60 B

P/E Ratio
-38.73

YTD Change
0%

52 Week Range
$5.53 - $95.52

Stock Name
Forty Seven Inc

CEO

Employees
68

Address
Menlo Park , CA

Forty Seven, Inc. or FTSV is traded on NASDAQ. The total market value of the company is $ 4.60 B. is the CEO of the company. Total employees of Forty Seven, Inc. are 68. The P/E Ratio of Forty Seven Inc is -38.73 and year till date stock price change percent is 0%.

Biohaven Pharmaceutical Holding Company Ltd

BHVN

Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and MPO inhibition for multiple system atrophy and amyotrophic lateral sclerosis.

Symbol
BHVN

Exchange
NEW YORK STOCK EXCHANGE INC.

Sector
Manufacturing

Website
biohavenpharma.com

Market Cap
$ 4.56 B

P/E Ratio

YTD Change
28.48%

52 Week Range
$12.35 - $58.83

Stock Name
Biohaven Pharmaceutical Holding Company Ltd

CEO
Vlad Coric

Employees
825

Address
New Haven , Connecticut

Biohaven Pharmaceutical Holding Company Ltd or BHVN is traded on NEW YORK STOCK EXCHANGE INC.. The total market value of the company is $ 4.56 B. Vlad Coric is the CEO of the company. Total employees of Biohaven Pharmaceutical Holding Company Ltd are 825. The P/E Ratio of Biohaven Pharmaceutical Holding Company Ltd is and year till date stock price change percent is 28.48%.

Krystal Biotech Inc

KRYS

Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases.

Symbol
KRYS

Exchange
NASDAQ

Sector
Manufacturing

Website
www.krystalbio.com

Market Cap
$ 4.53 B

P/E Ratio

YTD Change
30.58%

52 Week Range
$70.51 - $173.00

Stock Name
Krystal Biotech Inc

CEO

Employees
75

Address
Pittsburgh , Pennsylvania

Krystal Biotech Inc or KRYS is traded on NASDAQ. The total market value of the company is $ 4.53 B. is the CEO of the company. Total employees of Krystal Biotech Inc are 75. The P/E Ratio of Krystal Biotech Inc is and year till date stock price change percent is 30.58%.

Turning Point Therapeutics Inc

TPTX

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

Symbol
TPTX

Exchange
NASDAQ

Sector
Manufacturing

Website
tptherapeutics.com

Market Cap
$ 3.81 B

P/E Ratio

YTD Change
0%

52 Week Range
$0.00 - $76.01

Stock Name
Turning Point Therapeutics Inc

CEO

Employees
142

Turning Point Therapeutics Inc or TPTX is traded on NASDAQ. The total market value of the company is $ 3.81 B. is the CEO of the company. Total employees of Turning Point Therapeutics Inc are 142. The P/E Ratio of Turning Point Therapeutics Inc is and year till date stock price change percent is 0%.

SpringWorks Therapeutics Inc

SWTX

SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks' strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio.

Symbol
SWTX

Exchange
NASDAQ

Sector
Manufacturing

Website
www.springworkstx.com

Market Cap
$ 3.64 B

P/E Ratio

YTD Change
36.38%

52 Week Range
$18.00 - $53.78

Stock Name
SpringWorks Therapeutics Inc

CEO

Employees
78

SpringWorks Therapeutics Inc or SWTX is traded on NASDAQ. The total market value of the company is $ 3.64 B. is the CEO of the company. Total employees of SpringWorks Therapeutics Inc are 78. The P/E Ratio of SpringWorks Therapeutics Inc is and year till date stock price change percent is 36.38%.

Ideaya Biosciences Inc

IDYA

IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality - which represents an emerging class of precision medicine targets.

Symbol
IDYA

Exchange
NASDAQ

Sector
Professional, Scientific, and Technical Services

Website
www.ideayabio.com

Market Cap
$ 3.48 B

P/E Ratio
-23.82

YTD Change
30.9%

52 Week Range
$13.29 - $47.74

Stock Name
Ideaya Biosciences Inc

CEO
Yujiro Hata

Employees
62

Address
South San Francisco , California

Ideaya Biosciences Inc or IDYA is traded on NASDAQ. The total market value of the company is $ 3.48 B. Yujiro Hata is the CEO of the company. Total employees of Ideaya Biosciences Inc are 62. The P/E Ratio of Ideaya Biosciences Inc is -23.82 and year till date stock price change percent is 30.9%.

Principia Biopharma, Inc.

PRNB

Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA.

Symbol
PRNB

Exchange
NASDAQ

Sector
Health Technology

Website
http://www.principiabio.com

Market Cap
$ 3.32 B

P/E Ratio
-41.96

YTD Change
0%

52 Week Range
$25.35 - $101.89

Stock Name
Principia Biopharma, Inc.

CEO
Martin Babler

Employees
103

Address
South San Francisco , CA

Principia Biopharma, Inc. or PRNB is traded on NASDAQ. The total market value of the company is $ 3.32 B. Martin Babler is the CEO of the company. Total employees of Principia Biopharma, Inc. are 103. The P/E Ratio of Principia Biopharma, Inc. is -41.96 and year till date stock price change percent is 0%.

Crinetics Pharmaceuticals Inc

CRNX

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist undergoing two Phase 2 clinical trials for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 trial in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing CRN04777, an oral nonpeptide somatostatin receptor type 5 (SST5) agonist for hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company's drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company

Symbol
CRNX

Exchange
NASDAQ

Sector
Professional, Scientific, and Technical Services

Website
www.crinetics.com

Market Cap
$ 3.03 B

P/E Ratio
-11.81

YTD Change
24.02%

52 Week Range
$15.23 - $47.48

Stock Name
Crinetics Pharmaceuticals Inc

CEO
R. Scott Struthers

Employees
93

Address
San Diego , California

Crinetics Pharmaceuticals Inc or CRNX is traded on NASDAQ. The total market value of the company is $ 3.03 B. R. Scott Struthers is the CEO of the company. Total employees of Crinetics Pharmaceuticals Inc are 93. The P/E Ratio of Crinetics Pharmaceuticals Inc is -11.81 and year till date stock price change percent is 24.02%.

Provention Bio Inc

PRVB

Provention Bio, Inc. is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay or prevention of clinical type 1 diabetes in at-risk individuals, has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus.

Symbol
PRVB

Exchange
NASDAQ

Sector
Manufacturing

Website
www.proventionbio.com

Market Cap
$ 2.37 B

P/E Ratio

YTD Change
0%

52 Week Range
$0.00 - $25.00

Stock Name
Provention Bio Inc

CEO
Ashleigh Palmer

Employees
59

Address
Red Bank , New Jersey

Provention Bio Inc or PRVB is traded on NASDAQ. The total market value of the company is $ 2.37 B. Ashleigh Palmer is the CEO of the company. Total employees of Provention Bio Inc are 59. The P/E Ratio of Provention Bio Inc is and year till date stock price change percent is 0%.

Ra Pharmaceuticals, Inc.

RARX

Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA.

Symbol
RARX

Exchange
NASDAQ

Sector
Health Technology

Website
http://www.rapharma.com

Market Cap
$ 2.26 B

P/E Ratio
-20.91

YTD Change
0%

52 Week Range
$19.64 - $48.02

Stock Name
Ra Pharmaceuticals, Inc.

CEO
Douglas A. Treco

Employees
89

Address
Cambridge , MA

Ra Pharmaceuticals, Inc. or RARX is traded on NASDAQ. The total market value of the company is $ 2.26 B. Douglas A. Treco is the CEO of the company. Total employees of Ra Pharmaceuticals, Inc. are 89. The P/E Ratio of Ra Pharmaceuticals, Inc. is -20.91 and year till date stock price change percent is 0%.

Akcea Therapeutics Inc

AKCA

Symbol
AKCA

Exchange
NASDAQ/NGS (GLOBAL SELECT MARKET)

Sector
Manufacturing

Website
http://akceatx.com/

Market Cap
$ 1.85 B

P/E Ratio

YTD Change
0%

52 Week Range
$0.00 - $18.17

Stock Name
Akcea Therapeutics Inc

CEO
Damien McDevitt

Employees

Address
Boston , Massachusetts

Akcea Therapeutics Inc or AKCA is traded on NASDAQ/NGS (GLOBAL SELECT MARKET). The total market value of the company is $ 1.85 B. Damien McDevitt is the CEO of the company. Total employees of Akcea Therapeutics Inc are . The P/E Ratio of Akcea Therapeutics Inc is and year till date stock price change percent is 0%.

Akero Therapeutics Inc

AKRO

Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein, is currently being evaluated in Phase 2 clinical trials as a potential treatment for NASH. Akero is headquartered in South San Francisco.

Symbol
AKRO

Exchange
NASDAQ

Sector
Manufacturing

Website
www.akerotx.com

Market Cap
$ 1.76 B

P/E Ratio

YTD Change
31.36%

52 Week Range
$11.25 - $58.38

Stock Name
Akero Therapeutics Inc

CEO

Employees
22

Address
South San Francisco , California

Akero Therapeutics Inc or AKRO is traded on NASDAQ. The total market value of the company is $ 1.76 B. is the CEO of the company. Total employees of Akero Therapeutics Inc are 22. The P/E Ratio of Akero Therapeutics Inc is and year till date stock price change percent is 31.36%.

Amneal Pharmaceuticals Inc

AMRX

Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Symbol
AMRX

Exchange
NEW YORK STOCK EXCHANGE INC.

Sector
Manufacturing

Website
www.amneal.com

Market Cap
$ 1.66 B

P/E Ratio
80.84

YTD Change
-11.16%

52 Week Range
$1.24 - $6.30

Stock Name
Amneal Pharmaceuticals Inc - Class A

CEO

Employees
6,000

Address
Bridgewater , New Jersey

Amneal Pharmaceuticals Inc or AMRX is traded on NEW YORK STOCK EXCHANGE INC.. The total market value of the company is $ 1.66 B. is the CEO of the company. Total employees of Amneal Pharmaceuticals Inc are 6,000. The P/E Ratio of Amneal Pharmaceuticals Inc - Class A is 80.84 and year till date stock price change percent is -11.16%.

Constellation Pharmaceuticals Inc

CNST

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

Symbol
CNST

Exchange
NASDAQ/NGS (GLOBAL SELECT MARKET)

Sector
Professional, Scientific, and Technical Services

Website
www.constellationpharma.com

Market Cap
$ 1.63 B

P/E Ratio

YTD Change
0%

52 Week Range
$0.00 - $34.05

Stock Name
Constellation Pharmaceuticals Inc

CEO

Employees

Constellation Pharmaceuticals Inc or CNST is traded on NASDAQ/NGS (GLOBAL SELECT MARKET). The total market value of the company is $ 1.63 B. is the CEO of the company. Total employees of Constellation Pharmaceuticals Inc are . The P/E Ratio of Constellation Pharmaceuticals Inc is and year till date stock price change percent is 0%.

Mirum Pharmaceuticals Inc

MIRM

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum's lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. Mirum has submitted an NDA for maralixibat in the treatment of cholestatic pruritus in patients with ALGS. Additionally, Mirum's marketing authorization application for the treatment of pediatric patients with PFIC2 has been accepted for review (validated) by the European Medicines Agency.

Symbol
MIRM

Exchange
NASDAQ

Sector
Professional, Scientific, and Technical Services

Website
mirumpharma.com

Market Cap
$ 1.34 B

P/E Ratio
-6.75

YTD Change
-2.9%

52 Week Range
$20.81 - $35.56

Stock Name
Mirum Pharmaceuticals Inc

CEO

Employees
68

Mirum Pharmaceuticals Inc or MIRM is traded on NASDAQ. The total market value of the company is $ 1.34 B. is the CEO of the company. Total employees of Mirum Pharmaceuticals Inc are 68. The P/E Ratio of Mirum Pharmaceuticals Inc is -6.75 and year till date stock price change percent is -2.9%.

EyePoint Pharmaceuticals Inc

EYPT

EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasert® sustained release technology with vorolanib, a tyrosine kinase inhibitor. Vorolanib provided clear efficacy signals in two prior human trials in wet AMD as an orally delivered therapy with no significant ocular adverse events. EYP-1901 is currently in a Phase 1 clinical trial initially targeting treatment of wet AMD, with the potential for additional indications in diabetic retinopathy and retinal vein occlusion.

Symbol
EYPT

Exchange
NASDAQ

Sector
Manufacturing

Website
eyepointpharma.com

Market Cap
$ 1.27 B

P/E Ratio

YTD Change
14.34%

52 Week Range
$2.21 - $30.99

Stock Name
EyePoint Pharmaceuticals Inc

CEO

Employees
100

EyePoint Pharmaceuticals Inc or EYPT is traded on NASDAQ. The total market value of the company is $ 1.27 B. is the CEO of the company. Total employees of EyePoint Pharmaceuticals Inc are 100. The P/E Ratio of EyePoint Pharmaceuticals Inc is and year till date stock price change percent is 14.34%.

Best Major Pharmaceuticals Stocks List

LogoStockMarket Value
No matching records found

Tags

Best Pharmaceuticals: Major Stocks 2019
Top Pharmaceuticals: Major Stocks
Biggest Pharmaceuticals: Major Stocks
Best Pharmaceuticals: Major Stocks in United States
Pharmaceuticals: Major Stocks to watch on
Best Pharmaceuticals: Major Stocks to Invest in